A-PONASA

A-PONASA
Identifiers
	IUPAC name N-(adamantan-1-yl)-4-(pentyloxy)naphthalene-1-sulfonamide;
Chemical and physical data
Formula	C25H33NO3S
Molar mass	427.60 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCOc1ccc(c2ccccc21)S(=O)(=O)NC12CC3CC(C1)CC(C2)C3;
	InChI InChI=1S/C25H33NO3S/c1-2-3-6-11-29-23-9-10-24(22-8-5-4-7-21(22)23)30(27,28)26-25-15-18-12-19(16-25)14-20(13-18)17-25/h4-5,7-10,18-20,26H,2-3,6,11-17H2,1H3; Key:KDLJELWGBJUNBO-UHFFFAOYSA-N;

A-PONASA is a synthetic cannabinoid receptor agonist that has been sold as a designer drug. It is closely related to the previously reported compound CB-13 but with the naphthalene head group replaced with adamantyl, and an unusual sulfonamide linker group.^[1]^[2]

References

↑ "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. 2022.
↑ Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715. S2CID 254610773.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms" (PDF). Advisory Council on the Misuse of Drugs. 2022.

[pmid36507715-2] Andrews R, Jorge R, Christie R, Gallegos A (April 2023). "From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day". Drug Testing and Analysis. 15 (4): 378–387. doi:10.1002/dta.3422. PMID 36507715. S2CID 254610773.

[1]

[2]

See also

References